Skip main navigation

Outcomes Associated With Surgical and Pharmacologic Treatment of Obesity in Heart Failure

Originally publishedhttps://doi.org/10.1161/CIRCHEARTFAILURE.123.011323Circulation: Heart Failure. 2024;17
First page image

Footnotes

For Sources of Funding and Disclosures, see page 145.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

Correspondence to: Tiffany M. Powell-Wiley, MD, MPH, FAHA, Clinical Research Center, (10-CRC) Room 5-5332, 10 Center Dr, Bethesda, MD 20892. Email

REFERENCES

  • 1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association.Circulation. 2023; 147:e93. doi: 10.1161/CIR.0000000000001123LinkGoogle Scholar
  • 2. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association.Circulation. 2023; 148:1606. doi: 10.1161/CIR.0000000000001184LinkGoogle Scholar
  • 3. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, van Veldhuisen DJ. Metabolic/bariatric surgery protects against cardiovascular disease.Eur Heart J. 2022; 43:1955–1969. doi: 10.1093/eurheartj/ehac071CrossrefMedlineGoogle Scholar
  • 4. Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors.Circulation. 2015; 132:1639–1647. doi: 10.1161/CIRCULATIONAHA.114.015000LinkGoogle Scholar
  • 5. Mentias A, Desai M, Aminian A, Patel KV, Keshvani N, Verma S, Cho L, Jacob M, Alvarez P, Lincoff AM, et al. Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity.Circ Heart Fail. 2023; 17:1189. doi: 10.1161/CIRCHEARTFAILURE.122.010453LinkGoogle Scholar
  • 6. Reijrink M, de Boer SA, Spoor DS, Lefrandt JD, Lambers Heerspink HJ, Boellaard R, Greuter MJ, Borra RJH, Hillebrands JL, Slart RHJA, et al. Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors.Atherosclerosis. 2019; 290:87–93. doi: 10.1016/j.atherosclerosis.2019.09.016CrossrefMedlineGoogle Scholar
  • 7. Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, et al. Relation of regional fat distribution to left ventricular structure and function.Circ Cardiovasc Imaging. 2013; 6:800–807. doi: 10.1161/CIRCIMAGING.113.000532LinkGoogle Scholar
  • 8. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction.Circ Res. 2021; 128:951–968. doi: 10.1161/CIRCRESAHA.121.318093LinkGoogle Scholar
  • 9. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.Nat Med. 2023; 29:2358–2365. doi: 10.1038/s41591-023-02526-xCrossrefMedlineGoogle Scholar
  • 10. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.Circulation. 2017; 136:6–19. doi: 10.1161/CIRCULATIONAHA.116.026807LinkGoogle Scholar
  • 11. Pandey A, Patel KV, Vaduganathan M, Sarma S, Haykowsky MJ, Berry JD, Lavie CJ. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction.JACC Heart Fail. 2018; 6:975–982. doi: 10.1016/j.jchf.2018.09.006CrossrefMedlineGoogle Scholar
  • 12. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019; 140:e596–e646. doi: 10.1161/CIR.0000000000000678LinkGoogle Scholar
  • 13. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis.PLoS One. 2014; 9:e0104519. doi: 10.1371/journal.pone.0104519CrossrefMedlineGoogle Scholar
  • 14. Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld JA, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL, et al. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.JACC Heart Fail. 2020; 8:961–972. doi: 10.1016/j.jchf.2020.10.002CrossrefMedlineGoogle Scholar
  • 15. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease a scientific statement from the American Heart Association.Circulation. 2021; 143:e984–e1010. doi: 10.1161/CIR.0000000000000973LinkGoogle Scholar